Skip to content

MPN-MDS

EU Focus Meeting 2026


📍 Courtyard by Marriott Vienna Prater/Messe, Trabrennstrasse 4, Vienna, Austria, 1020

🗓️ October 23 - 24, 2026


Last Year's Highlights

CME Accreditation

MD Education will seek accreditation from the European Accreditation Council for Continuing Medical Education (EACCME). This will allow participants of the academy to earn CME credits, enhancing the educational value of their experience.

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the MPN-MDS Focus Meeting 2026, to be held on September 23 - 24, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing MPN-MDS research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of MPN-MDS EU Focus Meeting 2026:

Rami-Komrokji

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL


Alessandro-Vannucchi

Dr. Alessandro M. Vannucchi
University of Florence, Italy


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
ben.whitley@md-education.com

Agenda & Faculty

October 23, 2026 | Day 1  

07:00 AM
Registration Opens
08:40 AM
Coffee Break

Session I: Pathophysiology of MPN and MDS
Moderated by: TBD

09:00 AM
Targeting Hepcidin in MPN (PV and MF)

BM

Barbara Mora, MD
Fondazione IRCCS Ca’ Granda - Ospedale
Maggiore Policlinico, Milan, Italy

09:15 AM
JAK2 Mutated Specific Inhibitor(s): Dream or Realty?

WV

William Vainchenker, MD
Université catholique de Louvain, Belgium

09:30 AM
Blastic Plasmocytoid Dendritic Cell Neoplasm (BDPCN)

VB

Vera Ulrike Bacher, MD
University Clinic for Hematology and Central Hematology Laboratory, Inselspital, Bern, Switzerland

Debate 1: The Chicken or Egg in Myeloid Malignancies

09:45 AM
It all Starts in the HSC Clone from CHIP to Myeloid Malignancies

AO

Astrid Marta Olsnes, MD
University of Bergen, Norway

10:00 AM
It all Starts in the Bone Marrow Milieu from Inflammation and Immune Derangements
Shahram-Kordasti

Shahram Kordasti, MD
King’s College London, UK

10:15 AM
Panel Discussion
10:35 AM
Coffee Break

Session II: Debates in MPN
Moderated by: TBD

Debate 1: Is Two Better Than One: Combination Therapies in MF

10:55 AM
Yes

SS

Stefan Scheding, MD
Lund University, Sweden

11:10 AM
No
Giuseppe-Palumbo

Giuseppe Palumbo, MD
University of Catania, Italy

Debate 1: Splancnic Vein Thrombosis in MPN: Cytoreduction is Needed

11:25 AM
Yes
Danijela-Lekovic

Danijela Lekovic, MD
University Clinical Center Serbia, Belgrade, Serbia

11:40 AM
No
Rajko-Kusec

Rajko Kusec, MD
University of Zagreb, Croatia

11:55 AM
Panel Discussion
12:15 PM
Lunch Break + Faculty and Fellow Photo
01:05 PM
Industry Supported Independent Expert Discussion

Session III: Essential Thrombocythemia and Special Situation
Moderated by: TBD

01:50 PM
Evidence-Based Management of Essential Thrombocythemia in 2026
Anna-Godfrey

Anna Godfrey, MD
Cambridge University Hospitals NHS Foundation Trust, UK

02:05 PM
Novel Drugs for ET (I): Interferon, Bomedestat, CALR Immunotherapies
Giuseppe-Gaetano-Loscocco

Giuseppe Gaetano Loscocco, MD
University of Florence, Italy

02:20 PM
Recommendations for Female Gender-Related Management Issues in MPN

MG

Martin Griesshammer, MD
Johannes Wesling Medical Center Minden, Germany

02:35 PM
Panel Discussion
02:55 PM
Coffee Break

Session IV: Management Issues in Myekofibrosis
Moderated by: TBD

03:15 PM
Management of Anemia in MF

PG

Paola Guglielmelli, MD
University of Florence, Italy

03:30 PM
Management of JAKi Side Effects in MPN

IU

Ivana Urosevic, MD
University of Novi Sad, Serbia

03:45 PM
Management of Transplantation in MF

NP

Nicola Polverelli, MD
San Matteo Hospital Foundation (IRCCS), Pavia, Italy

04:00 PM
Special Interest Lecture: MPN-Blast phase: are we making progress?
Alessandro-Vannucchi

Alessandro M.  Vannucchi, MD
University of Florence, Italy

04:15 PM
Panel Discussion
04:35 AM
Industry Supported Independent Expert Discussion
05:20 PM
Adjourn

October 24, 2026 | Day 2

07:00 AM
Registration Opens
08:45 AM
Coffee Break

Session V: Less Common MPNs: Updates on Diagnosis and Treatment
Moderated by: TBD

09:00 AM
Aggressive Systemic Mastocytosis

DR

Deepti Radia, MD
Guy’s and St Thomas’ NHS Foundation Trust, London, UK

09:15 AM
Rare myeloproliferative Neoplasia with Eosinophilia

AR

Andreas Reiter, MD
University Medical Centre Mannheim, Germany

09:30 AM
Special Interest Lecture: The JAK2 46/1, and Other Predisposition Haplotypes for MPN, Revisited
Nick-Cross

Nick Cross, PhD
University of Southampton, UK

09:45 AM
Panel Discussion
10:05 AM
Coffee Break

Session VI: TBD
Moderated by: TBD

10:25 AM
MPN in the Youngest

JI

Marta Sobas, MD
Wroclaw Medical University, Poland

10:40 AM
Addressing Optimal Symptom Management in MPN in Clinical Practice

GC

Giovanni Caocci, MD
University of Cagliari, Italy

10:55 AM
Treatment endpoints for CML in 2026

MB

Massimo Breccia, MD
Sapienza University of Rome, Italy

11:10 PM
Special Interest Lecture: TP53 Myeloid Neoplasms
Luca-Guarnera

Luca Guarnera, MD
University of Rome Tor Vergata, Rome, Italy

11:25 AM
Panel Discussion
11:45 AM
Lunch Break
12:35 PM
Industry Supported Independent Expert Discussion

Session VII: Debate in Myelodysplastic Syndrome
Moderated by: TBD

Debate 1: When to Treat Anemia in Lower Risk MDS
01:20 PM
I Treat Non-RBC-TD Anemia

MM

Maria Julia Montoro, MD
University Hospital Vall d’Hebron,
Barcelona, Spain

01:35 PM
I Treat Only RBC-TD Anemia

SP

Sophie Park, MD
CHU Grenoble-Alpes, La Tronche, France

Debate 2: Venetoclax in HR MDS
01:50 PM
Venetoclax is Dead in HRMDS After VERONA Study Results

ML

Michael Lübbert, MD
University Medical Center Freiburg, Freiburg im Breisgau, Germany

02:05 PM
Venetoclax is Still Alive in HRMDS
Lionel-Ades

Lionel Ades, MD
Hospital Saint-Louis AP-HP, Paris, France

02:25 PM
Panel Discussion
02:45 PM
Coffee Break

Session VIII: MDS
Moderated by: TBD

03:05 PM
How do I Treat Lower Risk MDS?
Maria-Campelo

Maria Diez Campelo, MD
University of Salamanca, Spain

03:20 PM
How do I Treat Higher Risk MDS?
Thomas-Cluzeau

Thomas Cluzeau, MD
Nice University Hospital Center, France

03:35 PM
How do I Treat CMML?
Dan-Wiseman

Daniel Wiseman, MD
The Christie NHS Foundation Trust, Manchester, UK

03:50 PM
Panel Discussion
04:05 PM
Coffee Break

Session IX: Unique topics in MDS
Moderated by: TBD

04:20 PM
Sequencing Therapies in Lower Risk MDS
Matteo-DellaPorta

Matteo Della Porta, MD
Humanitas University, Milan, Italy

04:35 PM
VEXAS Syndrome
Carmelo-Gurnari

Carmelo Gurnari, MD
University of Rome Tor Vergata, Rome, Italy

04:50 PM
Special Interest Lecture: Peri Transplant MDS Treatment
Rami-Komrokji-1

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL

05:05 PM
Panel Discussion
05:25 PM
Industry Supported Independent Expert Discussion
06:10 PM
Adjourn

Ben Whitley
Project Manager

How long has Ben Whitley been in the business?

Ben Whitley has been with MD Education since 2025.

About Ben Whitley

As a Project Manager, I support the successful delivery of projects on time and within scope. I bring strong skills in project tracking, documentation management, and confident stakeholder engagement, and I take great pride in being part of a collaborative team. With a background in Business and IT, I apply this combined knowledge to streamline processes and support efficient project delivery. I value opportunities to meet and network with new people, enabling me to build and maintain strong professional relationships.

Ben-Whitley-web